201 related articles for article (PubMed ID: 34615860)
21. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
[TBL] [Abstract][Full Text] [Related]
23. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
[TBL] [Abstract][Full Text] [Related]
24. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
25. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
26. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
27. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Madhi SA; Kwatra G; Richardson SI; Koen AL; Baillie V; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Aley PK; Bhikha S; Bhorat AE; Esmail A; Horne E; Kaldine H; Mukendi CK; Madzorera VS; Manamela NP; Masilela M; Hermanus ST; Motlou T; Mzindle N; Oelofse S; Patel F; Rhead S; Rossouw L; Taoushanis C; van Eck S; Lambe T; Gilbert SC; Pollard AJ; Moore PL; Izu A
Lancet Infect Dis; 2023 Mar; 23(3):295-306. PubMed ID: 36273491
[TBL] [Abstract][Full Text] [Related]
28. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.
van Doremalen N; Purushotham JN; Schulz JE; Holbrook MG; Bushmaker T; Carmody A; Port JR; Yinda CK; Okumura A; Saturday G; Amanat F; Krammer F; Hanley PW; Smith BJ; Lovaglio J; Anzick SL; Barbian K; Martens C; Gilbert SC; Lambe T; Munster VJ
Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34315826
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A
Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190
[TBL] [Abstract][Full Text] [Related]
30. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
[TBL] [Abstract][Full Text] [Related]
31. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
[TBL] [Abstract][Full Text] [Related]
32. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
[TBL] [Abstract][Full Text] [Related]
33. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
Front Immunol; 2022; 13():811020. PubMed ID: 35126395
[TBL] [Abstract][Full Text] [Related]
35. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models.
Lambe T; Spencer AJ; Thomas KM; Gooch KE; Thomas S; White AD; Humphries HE; Wright D; Belij-Rammerstorfer S; Thakur N; Conceicao C; Watson R; Alden L; Allen L; Aram M; Bewley KR; Brunt E; Brown P; Cavell BE; Cobb R; Fotheringham SA; Gilbride C; Harris DJ; Ho CMK; Hunter L; Kennard CL; Leung S; Lucas V; Ngabo D; Ryan KA; Sharpe H; Sarfas C; Sibley L; Slack GS; Ulaszewska M; Wand N; Wiblin NR; Gleeson FV; Bailey D; Sharpe S; Charlton S; Salguero FJ; Carroll MW; Gilbert SC
Commun Biol; 2021 Jul; 4(1):915. PubMed ID: 34312487
[TBL] [Abstract][Full Text] [Related]
36. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
37. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
Wall EC; Wu M; Harvey R; Kelly G; Warchal S; Sawyer C; Daniels R; Adams L; Hobson P; Hatipoglu E; Ngai Y; Hussain S; Ambrose K; Hindmarsh S; Beale R; Riddell A; Gamblin S; Howell M; Kassiotis G; Libri V; Williams B; Swanton C; Gandhi S; Bauer DL
Lancet; 2021 Jul; 398(10296):207-209. PubMed ID: 34197809
[No Abstract] [Full Text] [Related]
38. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
[No Abstract] [Full Text] [Related]
39. Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.
Singh UB; Rophina M; Chaudhry R; Senthivel V; Bala K; Bhoyar RC; Jolly B; Jamshed N; Imran M; Gupta R; Aggarwal P; Divakar MK; Sinha S; Arvinden VR; Bajaj A; Shamnath A; Jain A; ; Scaria V; Sivasubbu S; Guleria R
J Med Virol; 2022 Apr; 94(4):1696-1700. PubMed ID: 34786733
[TBL] [Abstract][Full Text] [Related]
40. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants.
Eyre DW; Taylor D; Purver M; Chapman D; Fowler T; Pouwels KB; Walker AS; Peto TEA
N Engl J Med; 2022 Feb; 386(8):744-756. PubMed ID: 34986294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]